Anti-TAK1 (phospho S439) 抗体 [EPR2863] (ab109404)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2863] to TAK1 (phospho S439)
- Suitable for: Dot blot, WB, IP
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-TAK1 (phospho S439) antibody [EPR2863]
TAK1 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR2863] to TAK1 (phospho S439) -
由来種
Rabbit -
特異性
This antibody only detects TAK1 phosphorylated at Serine 439 in Human or TAK1 phosphorylated at Serine 412 in Mouse.
-
アプリケーション
適用あり: Dot blot, WB, IPmore details
適用なし: Flow Cyt,ICC/IF or IHC-P -
種交差性
交差種: Human
交差が予測される動物種: Mouse, Rat -
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
ポジティブ・コントロール
- HeLa cell lysate. IP: HeLa treated with 100nM Calyculin A and 20ng/ml human IL-1 beta for 10min whole cell lysate.
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
バッファー
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
精製度
Tissue culture supernatant -
ポリ/モノ
モノクローナル -
クローン名
EPR2863 -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab109404の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Dot blot |
Use at an assay dependent concentration.
|
|
WB |
1/1000 - 1/10000. Detects a band of approximately 75 kDa (predicted molecular weight: 67 kDa).
|
|
IP |
1/10 - 1/100.
|
特記事項 |
---|
Dot blot
Use at an assay dependent concentration. |
WB
1/1000 - 1/10000. Detects a band of approximately 75 kDa (predicted molecular weight: 67 kDa). |
IP
1/10 - 1/100. |
ターゲット情報
-
機能
Component of a protein kinase signal transduction cascade. Mediator of TRAF6 and TGF-beta signal transduction. Activates IKBKB and MAPK8 in response to TRAF6 signaling. Stimulates NF-kappa-B activation and the p38 MAPK pathway. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK, but not that of NF-kappa-B. -
配列類似性
Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase kinase subfamily.
Contains 1 protein kinase domain. -
翻訳後修飾
Association with TAB1/MAP3K7IP1 promotes autophosphorylation and subsequent activation. Association with TAB2/MAP3K7IP2, itself associated with free unanchored Lys-63 polyubiquitin chain, promotes autophosphorylation and subsequent activation of MAP3K7. Dephosphorylation at Thr-187 by PP2A and PPP6C leads to inactivation.
Ubiquitinated, leading to proteasomal degradation (By similarity). Requires 'Lys-63'-linked polyubiquitination for autophosphorylation and subsequent activation. 'Lys-63'-linked ubiquitination does not lead to proteasomal degradation. Deubiquitinated by CYLD, a protease that selectively cleaves 'Lys-63'-linked ubiquitin chains. Deubiquitinated by Y.enterocolitica YopP. - Information by UniProt
-
参照データベース
- Entrez Gene: 6885 Human
- Entrez Gene: 26409 Mouse
- Entrez Gene: 313121 Rat
- Omim: 602614 Human
- SwissProt: O43318 Human
- SwissProt: Q62073 Mouse
- SwissProt: P0C8E4 Rat
- Unigene: 722892 Human
see all -
別名
- M3K7_HUMAN antibody
- MAP3K 7 antibody
- Map3k7 antibody
see all
画像
-
All lanes : Anti-TAK1 (phospho S439) antibody [EPR2863] (ab109404) at 1/1000 dilution
Lane 1 : HeLa whole cell lysate
Lane 2 : HeLa treated with 100nM Calyculin A and 20ng/ml human IL-1ß for 10 minutes whole cell lysate
Lane 3 : HeLa treated with 100nM Calyculin A and 20ng/ml human IL-1ß for 10 minutes whole cell lysate. Then the membrane was incubated with alkaline phosphatase.
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 67 kDa
Observed band size: 75 kDa why is the actual band size different from the predicted?
Exposure time: 10 secondsDilution and blocking buffer: 5% NFDM/TBST.
-
Purified ab109404 at 1/50 dilution (2µg) immunoprecipitating TAK1 in HeLa treated with 100nM Calyculin A and 20ng/ml human IL-1 beta for 10min whole cell lysate.
Lane 1 (input): HeLa (Human cervix adenocarcinoma epithelial cell) treated with 100nM Calyculin A and 20ng/ml human IL-1 beta for 10min whole cell lysate 10µg
Lane 2 (+): ab109404 + HeLa treated with 100nM Calyculin A and 20ng/ml human IL-1 beta for 10min whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab239974 in HeLa treated with 100nM Calyculin A and 20ng/ml human IL-1 beta for 10min whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
Observed band size: 75 kDa -
Dot Blot analysis of Lane 1: TAK1 (phospho S439) phospho peptide and Lane 2: TAK1 non-phospho peptide labeling TAK1 (phospho S439) with ab109404 at 1/1000 dilution (0.009 μg/ml). 5% NFDM/TBST was used as the diluting and blocking buffer. ab97051 Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated was used as the secondary antibody at 1/100,000 dilution. Exposure time: 3 minutes.
-
All lanes : Anti-TAK1 (phospho S439) antibody [EPR2863] (ab109404) at 1/1000 dilution
Lane 1 : HeLa cell lysate
Lane 2 : HeLa cell lysate treated with transforming growth factor-beta (TGF-beta)
Lysates/proteins at 10 µg per lane.
Predicted band size: 67 kDa
Observed band size: 75 kDa why is the actual band size different from the predicted?
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (15)
ab109404 は 15 報の論文で使用されています。
- Ruan T et al. H5N1 infection impairs the alveolar epithelial barrier through intercellular junction proteins via Itch-mediated proteasomal degradation. Commun Biol 5:186 (2022). PubMed: 35233032
- Krishnan M et al. Molecular mechanism underlying the TLR4 antagonistic and antiseptic activities of papiliocin, an insect innate immune response molecule. Proc Natl Acad Sci U S A 119:e2115669119 (2022). PubMed: 35238667
- Xia S et al. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance. Cell Mol Gastroenterol Hepatol 12:1121-1143 (2021). PubMed: 33962073
- Ju H et al. TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma. Am J Cancer Res 10:454-472 (2020). PubMed: 32195020
- Li C et al. Farnesoid X receptor activation inhibits TGFBR1/TAK1-mediated vascular inflammation and calcification via miR-135a-5p. Commun Biol 3:327 (2020). PubMed: 32581266